The announcement comes weeks after President Donald Trump inked deals with Eli Lilly and Novo Nordisk to make their GLP-1 drugs easier for Americans to access.
Abortion medication access, like mifepristone, is unchanged under Trump, but FDA reviews, lawsuits and state enforcement are creating risks for drugmakers.
Shares of Novo Nordisk on Monday fell 10% after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer's disease failed to meet its main goal.
The pharmaceutical giant Eli Lilly's stock has been riding the skyrocketing demand for its weight loss injection Zepbound and diabetes treatment Mounjaro.
Toyin Ajayi, CEO of Cityblock, which provides healthcare to Medicaid and Medicare recipients, sees a positive spin in the current political partisanship.